Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Morphosys Ag ADR (MOR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,584,131
  • Shares Outstanding, K 125,980
  • Annual Sales, $ 75,490 K
  • Annual Income, $ -78,920 K
  • 36-Month Beta N/A
  • Price/Sales 46.11
  • Price/Cash Flow N/A
  • Price/Book 5.76

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -1.22
  • Number of Estimates 1
  • High Estimate -1.22
  • Low Estimate -1.22
  • Prior Year -0.15
  • Growth Rate Est. (year over year) -713.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.40 +7.77%
on 11/20/18
30.08 -5.42%
on 12/03/18
-1.61 (-5.36%)
since 11/09/18
3-Month
21.75 +30.80%
on 10/26/18
31.33 -9.19%
on 11/08/18
+1.29 (+4.75%)
since 09/10/18
52-Week
21.75 +30.80%
on 10/26/18
35.90 -20.75%
on 07/24/18
+2.14 (+8.13%)
since 04/19/18

Most Recent Stories

More News
BK Technologies Declares Quarterly Dividend of $0.02 per Share

WEST MELBOURNE, FL / ACCESSWIRE / December 7, 2018 / BK Technologies, Inc. (NYSE: BKTI) today announced that today its Board of Directors declared a quarterly dividend of $0.02 per share of the Company's...

IIPR : 50.49 (+1.10%)
AAPL : 169.60 (+0.66%)
TX : 28.20 (-3.39%)
EFR.TO : 4.75 (+4.86%)
CIIX : 0.5900 (+5.36%)
ITRO : 1.0500 (+6.17%)
CNDGF : 0.3000 (-27.48%)
ZC.VN : 0.220 (+4.76%)
PKTEF : 0.2200 (+4.76%)
CRON : 12.88 (+1.26%)
VFC : 76.33 (+0.43%)
ACBFF : 8.6900 (-12.80%)
CVSI : 4.9450 (-1.49%)
COUP : 64.57 (+7.42%)
Y.TO : 5.57 (-8.24%)
GRUB : 80.81 (+5.22%)
MDR : 7.66 (+1.59%)
ESK.VN : 0.110 (+4.76%)
EA : 83.73 (+1.47%)
CLSK : 2.0999 (+10.52%)
BABA : 151.43 (-1.06%)
MO : 53.36 (-1.51%)
XXMMF : 0.2711 (+5.36%)
AEM : 39.20 (-1.80%)
SING : 0.0161 (-5.85%)
EW : 161.92 (+3.00%)
DATA : 127.13 (+3.00%)
EIX : 58.84 (+0.56%)
XIM.VN : 0.350 (-9.09%)
ATVI : 47.88 (+1.38%)
HTHT : 30.62 (+1.69%)
SSRM : 11.04 (+0.36%)
JRSH : 5.80 (-5.69%)
ZTMUF : 0.1860 (+2.20%)
MAR : 110.81 (-0.40%)
EXE.TO : 6.64 (-1.63%)
GBT.TO : 14.51 (-5.04%)
NBEV : 5.04 (+7.46%)
AVGO : 239.25 (+4.68%)
ORRP : 0.2171 (-1.32%)
DIIBF : 12.4118 (-7.99%)
FDIT : 0.0110 (-19.71%)
CMCM : 6.82 (+3.81%)
KLGDF : 10.5858 (+1.11%)
SHOP : 151.50 (+3.15%)
ESKYF : 0.0790 (-16.93%)
APOG : 33.75 (-2.00%)
SIA.TO : 16.48 (-1.20%)
TSRO : 74.09 (+0.19%)
GE : 6.93 (-1.14%)
NKTR : 36.66 (-0.89%)
ACB : 5.73 (-0.35%)
TWLO : 91.84 (+2.81%)
BKTI : 3.50 (-1.41%)
GLUU : 7.53 (+6.36%)
KR : 28.79 (-1.30%)
MGI : 2.02 (+6.88%)
MKL : 1,055.72 (+0.71%)
MOR : 28.45 (+2.97%)
OCLN : 0.0014 (-6.67%)
IDTI : 47.86 (-0.21%)
AMRN : 16.68 (-1.36%)
APHA : 5.61 (+7.27%)
APTI : 37.85 (-0.47%)
L.TO : 62.34 (+2.18%)
MorphoSys Presents Updated Data from L-MIND Study of MOR208 plus Lenalidomide in r/r DLBCL at ASH 2018

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / December 1, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) today presented data from the ongoing single-arm phase 2 clinical trial...

MOR : 28.45 (+2.97%)
MorphoSys Announces Approval of Tremfya(R) (Guselkumab) in Japan for the Treatment of Patients with Palmoplantar Pustulosis

PLANEGG/MUNICH, GERMANY, / ACCESSWIRE / November 26, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announced today that its licensee's affiliate, Janssen Pharmaceutical...

MOR : 28.45 (+2.97%)
InflaRx N.V. Reports Third Quarter 2018 Financial & Operating Results

-- First patient dosed in phase II trial with IFX-1 in ANCA-associated vasculitis

MOR : 28.45 (+2.97%)
IFRX : 29.51 (-1.04%)
MorphoSys to Present at Upcoming Investor Conferences

PLANEGG / MUNICH, GERMANY / ACCESSWIRE / November 21, 2018 / MorphoSys to Present at Upcoming Investor Conferences

MOR : 28.45 (+2.97%)
MorphoSys Announces Its Licensee Janssen Initiated a Phase 2 Study (NOVA) to Evaluate Guselkumab in Hidradenitis Suppurativa

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 19, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announced today that its licensee Janssen Research & Development,...

MOR : 28.45 (+2.97%)
DGAP-News: MorphoSys AG Announces Third Quarter 2018 Results

MOR : 28.45 (+2.97%)
NVS : 86.90 (-0.21%)
MorphoSys to Host Q3 2018 Conference Call on November 6, 2018

MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) will publish its third quarter 2018 results on

MOR : 28.45 (+2.97%)
MorphoSys to Present at Upcoming Investor Conferences

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / September 27, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) will present at the following conferences:

MOR : 28.45 (+2.97%)
MorphoSys Announces its Licensee Janssen has Initiated a Phase 3 Trial (PROTOSTAR) to Evaluate Guselkumab in Pediatric Psoriasis Patients

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / September 25, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announced today that its licensee Janssen Research & Development,...

MOR : 28.45 (+2.97%)
MPSYY : 27.9300 (+0.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade MOR with:

Business Summary

MorphoSys AG is a biopharmaceutical company. It develops treatment for cancer, inflammations and autoimmune diseases. The company's proprietary portfolio consists of MOR208, MOR202, MOR103, MOR106 and MOR107. Its partnered programs lighthouse project includes Tremfya(R) and Gantenerumab. MorphoSys AG...

See More

Key Turning Points

2nd Resistance Point 29.07
1st Resistance Point 28.76
Last Price 28.45
1st Support Level 28.08
2nd Support Level 27.71

See More

52-Week High 35.90
Fibonacci 61.8% 30.49
Fibonacci 50% 28.83
Last Price 28.45
Fibonacci 38.2% 27.16
52-Week Low 21.75

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar